Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 243 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer March 7, 2025 Understanding Serving Sizes January 15, 2021 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On... August 6, 2019 Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με... June 24, 2019 Load more HOT NEWS Embrace Your Inner Flexibility Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... Foodie Friday: Pumpkin EVERYTHING! Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following...
